Lisa Walter
RBC Capital Markets, Research Division

This morning as well as Harry Silvers, Investor Relations. James and Harry, thanks so much for joining us today. How are you both doing?

James Edgemond
CFO & Treasurer

Good morning. Thank you, Lisa. And really thanks to RBC for hosting United Therapeutics this morning. Harry and I are really glad to be here. I'm going to turn it over to Harry to do an opening statement on forward-looking statements before we start, if that's okay.

Harrison Silvers
Manager of Investor Relations

Thanks for having us, Lisa. Just to remind investors in the crowd and listening in, we may make forward-looking statements. And for any risks and uncertainties associated with those statements, please review our latest filings on Form 10-K and Form 10-Q.

Lisa Walter
RBC Capital Markets, Research Division

Well, James, Harry, maybe just to kick things off, could you just give us a big picture overview of what's going on with the company and the base business and where things stand with expansion, label expansion of Tyvaso into IPF?

James Edgemond
CFO & Treasurer

Yes, Lisa, thank you. It's a great question. And I think you'll be hard-pressed, as Martine talked about on the last earnings call, to find a mid-cap biotech company with as many projects and initiatives that are ongoing inside UT. And I think as an example, we just proved beyond a shadow of a doubt in 2 separate clinical trials of clinical efficacy in 2 different disease states that had better clinical outcomes than really any other clinical trial and those